Caspofungin Diacetate Formulation Stabilization via Carbonate Buffering
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Caspofungin compositions are highly unstable, leading to the formation of degradation products and impurities during storage, which affects their stability and shelf life, despite previous attempts to address these issues with different buffering agents and excipients.
Innovation Solution
A pharmaceutical composition comprising caspofungin or its pharmaceutically acceptable salt, along with a buffering agent selected from carbonic acid, bicarbonate, carbon dioxide, or carbonate, which stabilizes the formulation, reducing the formation of impurities and maintaining stability during storage.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If traditional buffering agents (tartrate, acetate) are used in caspofungin compositions, then the composition can be prepared and stored, but degradation products and impurities form rapidly, reducing stability
Solution Approach 1:
The patent changes the chemical parameters of the buffering agent from traditional options (tartrate, acetate) to a carbonate-based buffer system (sodium carbonate/bicarbonate). This parameter change in the buffer chemistry fundamentally alters the pH control mechanism and reduces catalytic activity toward caspofungin degradation, thereby improving stability while minimizing impurity formation
Solution Approach 2:
The patent employs a simple, inexpensive carbonate buffer system that can be easily prepared and disposed of, replacing complex traditional buffers. The carbonate system provides effective pH control without requiring sophisticated stabilization mechanisms, achieving cost-effective stability improvement
2Ease of operation
If caspofungin compositions are prepared for reconstitution prior to administration, then they can be administered parenterally, but the compound is highly unstable resulting in formation of various degradation products
Solution Approach 1:
The patent prepares the caspofungin composition in a stable lyophilized form with the carbonate buffer system already incorporated. This preliminary action ensures that the drug is stabilized before administration, and the buffer system remains effective throughout storage and reconstitution, preventing degradation while maintaining ease of parenteral administration
Solution Approach 2:
The carbonate buffer system acts as an intermediary that mediates between the caspofungin molecule and the aqueous environment. It controls pH and ionic conditions to prevent hydrolysis and degradation, enabling stable storage and easy reconstitution without compromising reliability
3Strength
If buffer systems are used to prepare caspofungin compositions, then pH control is achieved, but the buffer system may increase degradation product formation during preparation and storage
Solution Approach 1:
The patent changes the buffer chemistry from carboxylate-based (acetate, tartrate) to carbonate-based buffering. This parameter change provides effective pH control through the carbonate equilibrium system while eliminating the catalytic degradation pathways associated with traditional buffers, thus maintaining pH control capability without increasing degradation
Solution Approach 2:
The patent converts the potential harm of buffer-induced degradation into a benefit by selecting a carbonate buffer system that provides pH control while actually protecting against degradation. The carbonate system's unique chemistry transforms what could be a harmful interaction into a protective effect, reducing impurity formation while maintaining pH stability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition achieves a low percentage of total impurities and maintains stability for an extended period, allowing for easy reconstitution and sterile storage, with a lyophilized form that is clear and free of insoluble matter after reconstitution.
Implementation Method 1
bubbling with 0.03-0.06 equivalents of carbon dioxide until the pH was 4.0-4.5
Implementation Method 2
a buffering agent selected from the group consisting of carbonic acid, bicarbonate, carbon dioxide, carbonate
Implementation Method 3
freezing the solution obtained in step (iv)
Implementation Method 4
freeze drying the frozen solution obtained in step (v)
Data Source
Figure 1
AI summary
The present invention relates to a stable pharmaceutical composition comprising caspofungin diacetate and a buffering agent, to a process for the manufacture of said pharmaceutical composition as well as to its use in the treatment of fungal Infections.